Presurgical therapy in metastatic renal cell carcinoma

Expert Review of Anticancer Therapy

Volumn 7, Issue 1, 2007, Pages 73-78

  Jonasch, Eric ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biomarkers; Neoadjuvant therapy; Presurgical therapy; Renal cell carcinoma; Targeted therapy

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CANCER VACCINE; FLOXURIDINE; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; INTERLEUKIN 2; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULAR TARGETING AGENT;

BLEEDING; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOREDUCTIVE SURGERY; HUMAN; INTESTINE PERFORATION; KIDNEY CARCINOMA; METASTASIS POTENTIAL; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; PREOPERATIVE TREATMENT; REVIEW; TREATMENT OUTCOME; WOUND DEHISCENCE;

CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; HUMANS; INCIDENCE; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; NEPHRECTOMY; UNITED STATES;

EID: 33846519375     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.7.1.73     Document Type: Review

References (28)

1. Jemal A, Siegler R, Ward E et al. Cancer statistics. CA Cancer J. Clin. 56(2), 106-130 (2006).
2. Motzer RJ, Bacik J, Murphy BA et al. Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 20(1), 289-296 (2002).
3. Motzer RJ, Mazumdar M, Bacik J et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17(8), 2530-2540 (1999).
4. Hanrahan EO, Hennessy BT, Valero V. Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials. Expert Opin. Pharmacother. 6(9), 1477-1491 (2005).
5. Mauriac L, MacGrogan G, Avril A et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann. Oncol. 10(1), 47-52 (1999).
6. Broet P, Scholl SM, de la Rochefordiere A et al. Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial. Breast Cancer Res. Treat. 58(2) 151-156 (1999).
7. Semiglazov VF, Topuzov EE, Bavil JL et al. Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann. Oncol. 5(7), 591-595 (1994).
8. Makris A, Powles TJ, Ashley SE et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann. Oncol. 9(11), 1179-1184 (1998).
9. Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cajacer. J. Clin. Oncol. 16(8), 2672-2685 (1998).
10. van der Hage JA, van de Velde CJ, Julien JP et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J. Clin. Oncol. 19(22), 4224-4237 (2001).
11. Gazet JC, Ford HT, Gray R et al. Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy. Ann. Oncol. 12(5), 685-691 (2001).
12. Danforth DN Jr, Zujewski J, O'Shaughnessy J et al. Selection of local therapy after neoadjuvant chemotherapy in patients with stage IIIA,B breast cancer. Ann. Surg. Oncol. 5(2), 150-118 (1998).
13. Rouzier R et al. Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery. J. Clin. Oncol. 19(18), 3828-3835 (2001).
14. Sweeney P, Millikan R, Donat M et al. Is there a therapeutic role for post-chemotherapy retroperitoneal lymph node dissection in metastatic transitional cell carcinoma of the bladder? J. Urol. 169(6), 2113-2117 (2003).
15. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet. 354(9178), 533-540 (1999).
16. Winquist F, Kirchner TS, Segal R et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J. Urol. 171(2 Pt 1), 561-569 (2004).
17. Betticher DC Adjuvant and neoadjuvant chemotherapy in NSCLC: a paradigm shift. Lung Cancer 50(Suppl. 2), S9-S16 (2005).
18. Roselli M et al. Systemic administration of recombinant interferon alfa in carcinoma patients upregulates the expression of the carcinoma-associated antigens tumor-associated glycoprotein-72 and carcinoembryonic antigen. J. Clin. Oncol. 14(7), 2031-2042 (1996).
19. Roth JA, Fossella F, Komaki R et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J. Natl. Cancer Inst. 86(9), 673-680 (1994).
20. Albain KS et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG 9309). ASCO (2005).
21. Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J. Clin. Oncol. 23(9), 2038-2048 (2005).
22. Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon α-2b compared with interferonα-2b alone for metastatic renal-cell cancer. N. Engl. J. Med. 345(23), 1655-1659 (2001).
23. Mickisch GH, Garin A, van Poppel H et al. Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 358(9286), 966-970 (2001).
24. Assikis V et al. A prospective study of salvage surgery and additional systemic therapy following initial response in metastatic renal cell carcinoma (RCC). ASCO (2002).
25. Bex A, Horenblas S, Meinhardt W et al. The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumor in situ. Eur. Urol. 42(6), 570-576 (2002).
26. Escudier B et al. Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). ASCO (2005).
27. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24(1), 16-24 (2006).
28. Hudes G et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced rend cell carcinoma (adv RCC). ASCO (2006).